Review
Oncology
Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, Delong Liu
Summary: Antibodies and CAR-T cells are increasingly used in cancer immunotherapy for hematological malignancies. Small molecule inhibitors targeting oncoproteins and enzymes have been approved for several major hematological malignancies. Updates on novel agents and regimens from clinical trials were presented at the recent ASH annual meeting and other conferences.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Josefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Danielle Mandikian, Yonglian Sun, Zhonghua Lin, Kellen Schneider, Pamela Zhang, Rajesh Vij, Danielle Sharpnack, Pamela Chan, Cecile de la Cruz, Jack Sadowsky, Dhaya Seshasayee, James T. Koerber, Thomas H. Pillow, Gail D. Phillips, Rebecca K. Rowntree, C. Andrew Boswell, Katherine R. Kozak, Andrew G. Polson, Paul Polakis, Shang-Fan Yu, Peter S. Dragovich, Nicholas J. Agard
Summary: Early success with brentuximab vedotin in treating classical Hodgkin lymphoma led to the development of multiple MMAE antibody-drug conjugates, but most of these have not been successful in clinical trials. This study describes the development of second-generation therapeutic ADCs targeting Ly6E, with a focus on using DNA-damaging agents to improve durability of response. The new ADCs showed promising preclinical efficacy in driving tumor regression and reducing the likelihood of resistance compared to traditional MMAE-based conjugates.
Review
Oncology
Panagiotis Filis, Ioannis Zerdes, Theodora Soumala, Alexios Matikas, Theodoros Foukakis
Summary: Antibody-drug conjugates (ADCs) have shown promising results in the treatment of solid tumors, with multiple clinical trials and approved drugs confirming their efficacy and safety.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Immunology
Stephane J. C. Mancini, Karl Balabanian, Isabelle Corre, Julie Gavard, Gwendal Lazennec, Marie-Caroline Le Bousse-Kerdiles, Fawzia Louache, Veronique Maguer-Satta, Nathalie M. Mazure, Fatima Mechta-Grigoriou, Jean-Francois Peyron, Valerie Trichet, Olivier Herault
Summary: Recent advances in understanding the hematopoietic niche have been made through in vitro analysis and animal models. Insights from the study of solid tumor niches can provide valuable information for understanding the hematopoietic niche.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Vaishali Kapoor, Abhay K. Singh, Calvin D. Lewis, Sapna Deore, Dennis E. Hallahan
Summary: Therapeutic antibodies are effective in treating advanced-stage cancer by activating T-lymphocytes and targeting cancer-specific antigens. Additionally, using radiation therapy can enhance the efficacy of these antibodies and antibody-drug conjugates in cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Nicholas McNamee, Ines Pires da Silva, Adnan Nagrial, Bo Gao
Summary: Small-cell lung cancer (SCLC) is an aggressive disease with limited treatment options and poor survival rates. While there have been significant advancements in the treatment of non-small cell lung cancer (NSCLC), SCLC has not seen the same level of progress. This is due, in part, to the complex and heterogeneous nature of SCLC tumors. This review explores the current treatment paradigm of SCLC, recent advances in immunotherapy, challenges in identifying predictive biomarkers, and potential future directions in SCLC treatment research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Antonio Tapia-Galisteo, Luis alvarez-Vallina, Laura Sanz
Summary: Immune cell engagers are modified antibodies that have one arm binding a tumor-associated antigen and another arm binding an activating receptor in immune effector cells. These engagers have the potential to revolutionize the treatment of hematological malignancies and are more potent than conventional monoclonal antibodies. The field is growing rapidly, with multiple formats and targets currently in clinical trials, and trispecific antibodies show even more promise by targeting additional tumor-associated antigens or costimulatory receptors.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Immunology
Devesh Aggarwal, Jie Yang, Md. Abdus Salam, Sagnik Sengupta, Md. Yusuf Al-Amin, Saad Mustafa, Mohammad Aasif Khan, Xun Huang, Jogendra Singh Pawar
Summary: Cancer is a deadly disease with non-targeted and toxic conventional therapies. Antibody-drug conjugates (ADCs) offer a precise and effective alternative for cancer treatment. ADCs link a monoclonal antibody to a cytotoxic drug via a chemical linker, targeting cancer cells without harming normal cells. Despite some limitations, ADCs have shown promising results in clinical trials and have been approved for treating various types of cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Microbiology
Jessica S. Little, Zoe F. Weiss, Sarah P. Hammond
Summary: The use of targeted biologic therapies has greatly expanded for hematological malignancies in recent years, but presents challenges in determining infection risks. Invasive fungal infections are a serious complication in these patients, with certain small molecule inhibitors potentially increasing the risk of infection. Understanding the impact of novel targeted therapies on the development of invasive fungal infections in this high-risk patient population is crucial.
Article
Pharmacology & Pharmacy
Ophelia Yin, Yuan Xiong, Seiko Endo, Kazutaka Yoshihara, Tushar Garimella, Malaz AbuTarif, Russ Wada, Frank LaCreta
Summary: This study characterized the pharmacokinetics of Trastuzumab deruxtecan in patients with HER2-positive breast cancer or other solid tumor malignancies. Results showed no significant differences in steady-state exposure of the drug in different patient populations, suggesting that dose adjustment based on specific patient characteristics is not necessary.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Biochemistry & Molecular Biology
Ayako Nogami, Koji Sasaki
Summary: Following the success of immunotherapies in hematologic malignancies, further studies are underway to improve efficacy and reduce complications. Studies of novel therapeutic strategies are also underway, leading to the realization of immunotherapy for diseases initially considered less promising. Understanding the molecular immunity of hematologic malignancies is imperative in this new era of transplantation- and chemotherapy-free treatment strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Emanuela Ferraro, Joshua Z. Drago, Shanu Modi
Summary: The development of new generation HER2-targeted ADCs has transformed the treatment of HER2-positive breast cancer and re-energized drug development. These agents not only show great efficacy in traditional HER2-positive breast cancer, but also have the potential to be clinically valuable in cells with low HER2 expression or ERBB2 mutations.
BREAST CANCER RESEARCH
(2021)
Review
Oncology
Mohamed H. Omer, Areez Shafqat, Omar Ahmad, Khaled Alkattan, Ahmed Yaqinuddin, Moussab Damlaj
Summary: Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have revolutionized the treatment of hematological malignancies by directing T cells to attack specific tumor antigens. The success of blinatumomab in acute lymphoblastic leukemia has led to the development of numerous BiTEs/BiAbs targeting different tumor-associated antigens. However, concerns arise regarding toxicities and resistance towards these therapies. This review provides the most recent evidence from clinical trials on the safety and efficacy of BiAbs/BiTEs, as well as strategies to overcome their limitations.
Review
Pharmacology & Pharmacy
Yiting Dun, Gang Huang, Jianjun Liu, Weijun Wei
Summary: Immuno-positron emission tomography (immunoPET) imaging is a revolutionary tumor detection technique that combines the specificity of tumor-targeting vectors and the sensitivity of PET imaging to comprehensively reveal tumor antigen expression. This review summarizes the use of immunoPET in imaging hematological malignancies and discusses the current conjugation strategies and the potential of modular chemistry for developing novel immunoPET probes. Additionally, the use of immunoPET imaging in guiding antibody drug development is also discussed.
DRUG DISCOVERY TODAY
(2022)
Review
Pediatrics
Athanasios Tragiannidis, Andreas H. Groll
Summary: Targeted therapies have become a popular treatment option for pediatric hematologic malignancies in the last decade, offering the promise of improved disease control and survival. However, these therapies also come with specific toxicities like cytokine-release syndrome and neurotoxicity, and can lead to secondary dysgammaglobulinemia as a main consequence.
Article
Medicine, Research & Experimental
Alap Ali Zahid, Robin Augustine, Yogesh B. Dalvi, K. Reshma, Rashid Ahmed, Syed Raza Ur Rehman, Hany E. Marei, Rashad Alfkey, Anwarul Hasan
Summary: The study explores the use of GelMA hydrogel patches loaded with SNAP to enhance diabetic wound healing by improving cell proliferation and migration, showing promising results in promoting wound healing in diabetic rats.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Materials Science, Multidisciplinary
Zeinab Shouman, Hany E. Marei, Ahmed Abd-Elmaksoud, Mohamed Kassab, Takashi Namba, Md. Abdul Masum, Yaser Hosny Ali Elewa, Osamu Ichii, Yasuhiro Kon
Summary: This study found that the severity of autoimmune diseases increases with age, potentially leading to infertility through the loss of spermatogenic and Sertoli cells, rather than disrupting the blood-testis barrier.
MICROSCOPY AND MICROANALYSIS
(2021)
Review
Biochemistry & Molecular Biology
Hany E. Marei, Asmaa Althani, Nahla Afifi, Giacomo Pozzoli, Thomas Caceci, Franco Angelini, Carlo Cenciarelli
Summary: Efforts are being made to develop efficient vaccines and treatments for SARS-CoV-2 infection, with therapeutic strategies focusing on inhibiting virus replication, enhancing immunity, and relieving COVID-19 symptoms. Multiple clinical trials are ongoing to assess the efficacy of antiviral substances, while vaccination campaigns using various vaccines are underway worldwide with efficacy rates between 72-95%. Further research and data are needed to confirm the safety of available vaccines.
MOLECULAR BIOLOGY REPORTS
(2021)
Review
Oncology
Hany E. Marei, Asmaa Althani, Nahla Afifi, Anwarul Hasan, Thomas Caceci, Giacomo Pozzoli, Carlo Cenciarelli
Summary: CAR-T cell therapy shows great promise for treating aggressive tumors like GBM, but faces challenges such as tumor cell heterogeneity, antigen escape, and the inhibitory tumor microenvironment. Solutions to these challenges are crucial for fully realizing the potential of CAR-T cell therapy in clinical applications.
Review
Oncology
Hany E. Marei, Asmaa Althani, Nahla Afifi, Anwarul Hasan, Thomas Caceci, Giacomo Pozzoli, Andrea Morrione, Antonio Giordano, Carlo Cenciarelli
Summary: The p53 protein, known as the guardian of the genome, plays a critical role in preserving genomic integrity, and mutations in the TP53 gene can lead to uncontrolled cell proliferation and cancer formation. With p53 deficiency being common in human cancer, restoring p53 function may be an effective approach for cancer treatment.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Hany E. Marei, Asmaa Althani, Nahla Afifi, Anwarul Hasan, Thomas Caceci, Armando Felsani, Giuseppe Tringali, Ingrid Cifola, Giacomo Pozzoli, Carlo Cenciarelli
Summary: This study aims to compare the genetic variants between tumor core-associated CSC and peritumor tissue-derived CSC, and identified a potentially harmful frameshift deletion at Gln461fs in the MLLT1 gene.
CANCER CELL INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Shaymaa Rezk, Samah Lashen, Mohamed EL-Adl, Gehad E. Elshopakey, Mona M. Elghareeb, Basma M. Hendam, Thomas Caceci, Carlo Cenciarelli, Hany E. Marei
Summary: Rosemary oil can enhance cognitive function in rat models of cognitive deficit after transplantation of human olfactory bulb neuronal stem cells (hOBNSCs). Pre-administration of rosemary oil before cell transplantation can further improve multiple biochemical indicators and neuroprotective effects. This study reveals the potential application of rosemary oil in the field of neurosciences.
METABOLIC BRAIN DISEASE
(2022)
Article
Cell & Tissue Engineering
Hany E. Marei, Asmaa Althani, Nahla Afifi, Anwarul Hasan, Thomas Caceci, Giacomo Pozzoli, Carlo Cenciarelli
Summary: This study generated hiPSC from skin fibroblasts of an AD patient carrying a N141I missense mutation in PSEN2 and corrected the mutation using genome editing technology. The N141I missense mutation was associated with increased basal cell death and apoptosis.
STEM CELL RESEARCH
(2021)
Review
Chemistry, Multidisciplinary
ElhamO Mahgoub, Arif Hussain, Majid Sharifi, Mojtaba Falahati, Hany E. Marei, Anwarul Hasan
Summary: TTFields are an active anticancer modality that disrupt mitosis in cancerous cells using low-intensity, intermediate frequency, and alternating electric fields, leading to increased chromatid aberrations and cell death. They can be combined with metallic nanoparticles for internalization into cancer cells and effectively used with chemotherapy and radiotherapy.
ARABIAN JOURNAL OF CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Ingrid Cifola, Federica Fratini, Beatrice Cardinali, Valentina Palmieri, Giuliana Gatti, Tommaso Selmi, Sara Donzelli, Andrea Sacconi, Valeriana Cesarini, Hany E. Marei, Massimilano Papi, Giovanni Blandino, Carlo Cenciarelli, Germana Falcone, Igea D'Agnano
Summary: Glioblastoma (GBM) is a common and aggressive brain tumor with limited treatment options. The heterogeneity of GBM tumor cells, especially the cancer stem cells (CSCs), plays a crucial role in clinical outcomes. This study explored the role of extracellular vesicles (EVs) in CSCs and GBM tumor cells, finding that the miRNA and protein content of EVs differ, with GBM-sEVs enriched for tumor suppressor miRNAs and oncoproteins, and CSC-sEVs enriched for pro-tumor miRNAs and proteins related to sternness, cell proliferation, and apoptosis.
Review
Oncology
Hany E. Marei
Summary: This article provides an overview of nanocarrier-mediated drug delivery for the treatment of glioma. Nanocarriers have shown great potential in crossing the blood-brain barrier and delivering drugs to the brain. The use of nanotherapeutic approaches in glioblastoma treatment, including chemotherapy, radiotherapy, gene therapy, immunotherapy, and combination therapy, is also summarized. Furthermore, various perspectives on the clinical applicability of nanomedicine are discussed.
CANCER CELL INTERNATIONAL
(2022)
Editorial Material
Biochemistry & Molecular Biology
Hany E. Marei, Carlo Cenciarelli
Review
Biochemistry & Molecular Biology
Hany E. Marei, Muhammad Umar Aslam Khan, Anwarul Hasan
Summary: Alzheimer's disease is a chronic illness with no known cure. The development of induced pluripotent stem cells (iPSCs) has provided a new approach for modeling the disease, allowing researchers to better understand its underlying mechanisms. Utilizing cells derived from patients, it is now possible to create accurate models of Alzheimer's disease for drug development and treatment.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2023)
Review
Oncology
Hany E. Marei, Asmaa Althani, Nahla Afifi, Anwarul Hasan, Thomas Caceci, Ingrid Cifola, Sara Caratelli, Giuseppe Sconocchia, Igea D'Agnano, Carlo Cenciarelli
Summary: EVs have a diverse range of molecules and play a crucial role in the development of tumors, particularly in gliomas. Current research is uncovering the potential utility of EVs in the diagnosis, prognosis, and treatment of glioblastoma.